Former Wisconsin Rep. Mike Gallagher joined 'America's Newsroom' to discuss Trump's tariff threat against China and his ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...
Stock futures declined Tuesday after President-elect Donald Trump said soon after he takes office he would enact a 25% tariff ...
Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the company’s marketing, shifting its focus to the Lilly brand, its patients and an ...
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...
Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback